West Pharmaceutical Opens 165,000 Sq Ft Facility in Dublin
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy WST?
West Pharmaceutical Services announced the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity. The Damastown expansion enhances West's contract capabilities beyond its component molding, device assembly, and packaging to now include advanced automation and expanded drug-handling capabilities at commercial scale.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 245.140
Low
285.00
Averages
348.70
High
375.00
Current: 245.140
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Expands Facility in Dublin to Meet Growing Demand
- New Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot building in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume treatments such as diabetes and obesity.
- Enhanced Drug Handling Capabilities: This expansion not only boosts component molding, device assembly, and packaging capabilities but also adds advanced automation and commercial-scale drug handling, ensuring support for complex injectable drug delivery systems.
- Integrated Service Platform: The new facility is part of West Vantage™, which provides a single-source solution spanning product conceptualization, development, manufacturing, assembly, packaging, validation, analytical testing, and regulatory support, accelerating time to market for pharmaceuticals.
- Market Leadership: West Pharmaceutical achieved $3.07 billion in net sales in fiscal year 2025, solidifying its position as a leading provider of high-quality injectable solutions with over 10,000 employees and a global network of 50 sites.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Global Demand
- Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot facility in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume injectable treatments, particularly for diabetes and obesity.
- Increased Global Capacity: This expansion boosts West's drug handling capabilities for high-volume injectable therapies, including next-generation GLP-1 treatments, reinforcing its role as a critical partner in ensuring patient access to these essential medicines.
- Integrated Service Capabilities: The new facility expands capabilities beyond component molding, device assembly, and packaging to include advanced automation and enhanced drug-handling capabilities at commercial scale, addressing the growing demand for complex injectable drug delivery systems.
- Accelerated Market Access: Through West Vantage™, the company provides a comprehensive single-source solution for pharmaceutical and biotechnology partners, spanning product conceptualization to market, helping clients accelerate time to market and ensuring the global supply of life-enhancing and life-saving therapies.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Growing Demand
- New Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot building in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume treatments such as diabetes and obesity.
- Enhanced Drug Handling Capabilities: This expansion not only boosts component molding, device assembly, and packaging capabilities but also adds advanced automation and commercial-scale drug handling, ensuring support for complex injectable drug delivery systems.
- Integrated Service Platform: The new facility is part of West Vantage™, which provides a single-source solution spanning product conceptualization, development, manufacturing, assembly, packaging, validation, analytical testing, and regulatory support, accelerating time to market for pharmaceuticals.
- Market Leadership: West Pharmaceutical achieved $3.07 billion in net sales in fiscal year 2025, solidifying its position as a leading provider of high-quality injectable solutions with over 10,000 employees and a global network of 50 sites.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Global Demand
- Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot facility in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume injectable treatments, particularly for diabetes and obesity.
- Increased Global Capacity: This expansion boosts West's drug handling capabilities for high-volume injectable therapies, including next-generation GLP-1 treatments, reinforcing its role as a critical partner in ensuring patient access to these essential medicines.
- Integrated Service Capabilities: The new facility expands capabilities beyond component molding, device assembly, and packaging to include advanced automation and enhanced drug-handling capabilities at commercial scale, addressing the growing demand for complex injectable drug delivery systems.
- Accelerated Market Access: Through West Vantage™, the company provides a comprehensive single-source solution for pharmaceutical and biotechnology partners, spanning product conceptualization to market, helping clients accelerate time to market and ensuring the global supply of life-enhancing and life-saving therapies.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
